{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:16:38Z","timestamp":1792066598489,"version":"4.4.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,10,31]],"date-time":"2016-10-31T00:00:00Z","timestamp":1477872000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,10,31]],"date-time":"2016-10-31T00:00:00Z","timestamp":1477872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006831","name":"U.S. Air Force","doi-asserted-by":"publisher","award":["FKE20120020H"],"award-info":[{"award-number":["FKE20120020H"]}],"id":[{"id":"10.13039\/100006831","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s00296-016-3592-2","type":"journal-article","created":{"date-parts":[[2016,10,31]],"date-time":"2016-10-31T15:19:46Z","timestamp":1477927186000},"page":"445-453","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Genomic sequencing of uric acid metabolizing and clearing genes in relationship to xanthine oxidase inhibitor dose"],"prefix":"10.1007","volume":"37","author":[{"given":"Matthew B.","family":"Carroll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas L.","family":"Shaak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,31]]},"reference":[{"key":"3592_CR1","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1136\/ard.2007.078469","volume":"66","author":"Eliseo Pascual","year":"2007","unstructured":"Pascual Eliseo, Sivera Francisca (2007) Why is gout so poorly controlled? Ann Rheum Dis 66:1269\u20131270","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3592_CR2","first-page":"82","volume":"35","author":"C Avena-Woods","year":"2010","unstructured":"Avena-Woods C, Hilas O (2010) Febuxostat (Uloric): a new treatment option for gout. Pharm Ther 35(2):82\u201385","journal-title":"Pharm Ther"},{"issue":"10","key":"3592_CR3","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Liot\u00e9 F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R (2012) American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 64(10):1431\u20131446","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"3592_CR4","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMcp1001124","volume":"364","author":"T Neogi","year":"2011","unstructured":"Neogi T (2011) Clinical practice. Gout N Engl J Med 364(5):443\u2013452","journal-title":"Gout N Engl J Med"},{"key":"3592_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","volume":"76","author":"KR Hande","year":"1984","unstructured":"Hande KR, Noone RM, Stone WJ (1984) Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 76:47\u201356","journal-title":"Am J Med"},{"issue":"8","key":"3592_CR6","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1002\/art.34488","volume":"64","author":"LK Stamp","year":"2012","unstructured":"Stamp LK, Taylor WJ, Jones PB, Dockerty JL, Drake J, Frampton C, Dalbeth N (2012) Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum 64(8):2529\u20132536","journal-title":"Arthritis Rheum"},{"issue":"2","key":"3592_CR7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s11926-009-0019-z","volume":"11","author":"J Chao","year":"2009","unstructured":"Chao J, Terkeltaub R (2009) A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheumatol Rep 11(2):135\u2013140 (Review. PubMed PMID: 19296886)","journal-title":"Curr Rheumatol Rep"},{"issue":"7","key":"3592_CR8","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1517\/13543784.14.7.893","volume":"14","author":"HR Schumacher Jr","year":"2005","unstructured":"Schumacher HR Jr (2005) Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout. Expert Opin Investig Drugs 14(7):893\u2013903 (Review. PubMed PMID: 16022578)","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"3592_CR9","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1291\/hypres.31.931","volume":"31","author":"J Yang","year":"2008","unstructured":"Yang J, Kamide K, Kokubo Y, Takiuchi S, Horio T, Matayoshi T et al (2008) Associations of hypertension and its complications with variations in the xanthine dehydrogenase gene. Hypertens Res 31(5):931\u2013940","journal-title":"Hypertens Res"},{"issue":"3","key":"3592_CR10","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/FPC.0b013e3282f55e2e","volume":"18","author":"M Kudo","year":"2008","unstructured":"Kudo M, Moteki T, Sasaki T, Konno Y, Ujiie S, Onose A et al (2008) Functional characterization of human xanthine oxidase allelic variants. Pharmacogenet Genom 18(3):243\u2013251","journal-title":"Pharmacogenet Genom"},{"key":"3592_CR11","doi-asserted-by":"publisher","DOI":"10.1142\/S0218957713500048","author":"MB Carroll","year":"2013","unstructured":"Carroll MB, DeCastro M, Hust N, Smith F, Belema T, Schramko ML, Harris CC, Bashford MT (2013) The relationship of two xanthine oxidase single nucleotide polymorphisms to hyperuricemia, gout, and dose of xanthine oxidase inhibitor. J Musculoskel Res. doi: 10.1142\/S0218957713500048","journal-title":"J Musculoskel Res"},{"issue":"4","key":"3592_CR12","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/j.1365-2036.2009.04057.x","volume":"30","author":"MA Smith","year":"2009","unstructured":"Smith MA, Marinaki AM, Arenas M, Shobowale-Bakre M, Lewis CM, Ansari A, Duley J, Sanderson JD (2009) Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease. Aliment Pharmacol Ther 30(4):375\u2013384","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"3592_CR13","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/art.1780200320","volume":"20","author":"SL Wallace","year":"1977","unstructured":"Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Y\u00fc TF (1977) Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 20(3):895\u2013900","journal-title":"Arthritis Rheum"},{"issue":"7","key":"3592_CR14","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s00228-013-1478-8","volume":"69","author":"DF Wright","year":"2013","unstructured":"Wright DF, Stamp LK, Merriman TR, Barclay ML, Duffull SB, Holford NH (2013) The population pharmacokinetics of allopurinol and oxypurinol in patients with gout. Eur J Clin Pharmacol 69(7):1411\u20131421. doi: 10.1007\/s00228-013-1478-8 (Epub 2013 Mar 10)","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"3592_CR15","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1124\/dmd.105.006056","volume":"33","author":"T Iwanaga","year":"2005","unstructured":"Iwanaga T, Kobayashi D, Hirayama M, Maeda T, Tamai I (2005) Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone. Drug Metab Dispos 33(12):1791\u20131795 (Epub 2005 Aug 31 PubMed PMID: 16135657)","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"3592_CR16","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/j.clinthera.2009.11.033","volume":"31","author":"ME Ernst","year":"2009","unstructured":"Ernst ME, Fravel MA (2009) Febuxostat: a selective xanthine-oxidase\/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout. Clin Ther 31(11):2503\u20132518. doi: 10.1016\/j.clinthera.2009.11.033 (Review PubMed PMID: 20109996)","journal-title":"Clin Ther"},{"key":"3592_CR17","volume-title":"Sample size determination in health studies: a practical manual","author":"SK Lwanga","year":"1991","unstructured":"Lwanga SK, Lemeshow S (1991) Sample size determination in health studies: a practical manual. World Health Organization, Geneva"},{"issue":"2","key":"3592_CR18","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.semarthrit.2014.05.007","volume":"44","author":"LK Stamp","year":"2014","unstructured":"Stamp LK, Merriman TR, Barclay ML, Singh JA, Roberts RL, Wright DF, Dalbeth N (2014) Impaired response or insufficient dosage? Examining the potential causes of \u201cinadequate response\u201d to allopurinol in the treatment of gout. Semin Arthritis Rheum 44(2):170\u2013174","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"3592_CR19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.semarthrit.2014.01.004","volume":"44","author":"CG Jennings","year":"2014","unstructured":"Jennings CG, Mackenzie IS, Flynn R, Ford I, Nuki G, De Caterina R, Riches PL, Ralston SH, MacDonald TM, FAST study group (2014) Up-titration of allopurinol in patients with gout. Semin Arthritis Rheum 44(1):25\u201330. doi: 10.1016\/j.semarthrit.2014.01.004 (Epub 2014 Jan 23 PubMed PMID: 24560169)","journal-title":"Semin Arthritis Rheum"},{"issue":"24","key":"3592_CR20","doi-asserted-by":"publisher","first-page":"8441","DOI":"10.1021\/jm100888d","volume":"53","author":"DC Pryde","year":"2010","unstructured":"Pryde DC, Dalvie D, Hu Q, Jones P, Obach RS, Tran TD (2010) Aldehyde oxidase: an enzyme of emerging importance in drug discovery. J Med Chem 53(24):8441\u20138460. doi: 10.1021\/jm100888d (Epub 2010 Sep 20 PubMed PMID: 20853847)","journal-title":"J Med Chem"},{"issue":"5","key":"3592_CR21","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1124\/dmd.111.043828","volume":"40","author":"T Hartmann","year":"2012","unstructured":"Hartmann T, Terao M, Garattini E, Teutloff C, Alfaro JF, Jones JP, Leimk\u00fchler S (2012) The impact of single nucleotide polymorphisms on human aldehyde oxidase. Drug Metab Dispos 40(5):856\u2013864","journal-title":"Drug Metab Dispos"},{"key":"3592_CR22","unstructured":"Accessed 26 Feb 2016. http:\/\/web.expasy.org\/variant_pages\/VAR_070258.html"},{"key":"3592_CR23","unstructured":"Barnes MR, Gray IC (2003) Bioinformatics for geneticists. Copyright 2003 Wiley. ISBNs: 0-470-84393-4 (HB); 0-470-84394-2 (PB)"},{"key":"3592_CR24","unstructured":"Accessed 27 Feb 2016. http:\/\/genetics.bwh.harvard.edu\/ggi\/pph2\/f84a95d592ec295fca490896a8796270b9c7ff3f\/3459189.html"},{"key":"3592_CR25","unstructured":"Accessed 27 Feb 2016. http:\/\/www.snps3d.org\/modules.php?name=SnpAnalysis&locus_ac=316"},{"key":"3592_CR26","unstructured":"Accessed 26 Feb 2016. http:\/\/www.veritastk.co.jp\/attached\/5389\/ISSX_2014_Aldehyde_Oxidase_Pharmacogenomics.pdf"},{"key":"3592_CR27","unstructured":"Accessed 26 Feb 2016. http:\/\/www.veritastk.co.jp\/attached\/5386\/Aox1_poster_ISSX_2014.pdf"},{"issue":"5","key":"3592_CR28","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/cpt.89","volume":"97","author":"CC Wen","year":"2015","unstructured":"Wen CC, Yee SW, Liang X, Hoffmann TJ, Kvale MN, Banda Y, Jorgenson E, Schaefer C, Risch N, Giacomini KM (2015) Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response. Clin Pharmacol Ther 97(5):518\u2013525","journal-title":"Clin Pharmacol Ther"},{"key":"3592_CR29","unstructured":"Accessed 27 Feb 2016. http:\/\/www.ncbi.nlm.nih.gov\/projects\/SNP\/index.html"},{"issue":"2","key":"3592_CR30","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/art.30119","volume":"63","author":"LK Stamp","year":"2011","unstructured":"Stamp LK, O\u2019Donnell JL, Zhang M, James J, Frampton C, Barclay ML, Chapman PT (2011) Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum 63(2):412\u2013421. doi: 10.1002\/art.30119 (PubMed PMID: 21279998)","journal-title":"Arthritis Rheum"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-016-3592-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-016-3592-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-016-3592-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T22:45:19Z","timestamp":1749681919000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-016-3592-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,31]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["3592"],"URL":"https:\/\/doi.org\/10.1007\/s00296-016-3592-2","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,31]]},"assertion":[{"value":"8 August 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Author Carroll, MB declares that he has no conflict of interest. Author Smith, DM declares that he has no conflict of interest. Author Shaak, T declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The voluntary, fully informed consent of the subjects used in this research was obtained as required by 32 CFR 219 and AFI 40-402, Protection of Human Subjects in Biomedical and Behavioral Research. Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}